<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>DROSPIRENONE - Research Report</title>
    <meta name="description" content="Comprehensive naturopathic research report for DROSPIRENONE">
    <style>
        
    * {
        box-sizing: border-box;
    }
    
    body {
        font-family: 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
        font-size: 16px;
        line-height: 1.6;
        margin: 0;
        padding: 0;
        background-color: #f8f9fa;
        color: #212529;
    }
    
    .container {
        max-width: 1200px;
        margin: 0 auto;
        padding: 20px;
        background-color: white;
        box-shadow: 0 0 10px rgba(0,0,0,0.1);
    }
    
    .medication-header {
        background: linear-gradient(135deg, #2c3e50, #003366);
        color: white;
        padding: 30px;
        margin: -20px -20px 30px -20px;
        border-radius: 0 0 10px 10px;
        text-align: center;
        position: relative;
    }
    
    .medication-header h1 {
        margin: 0 0 15px 0;
        font-size: 2.5em;
        font-weight: 600;
        text-shadow: 0 2px 4px rgba(0,0,0,0.3);
    }
    
    .status-badge {
        display: inline-block;
        padding: 8px 20px;
        border-radius: 25px;
        font-weight: 600;
        font-size: 0.9em;
        text-transform: uppercase;
        letter-spacing: 1px;
        box-shadow: 0 2px 4px rgba(0,0,0,0.2);
    }
    
    .status-allowed { background-color: #28a745; color: white; }
    .status-not-allowed { background-color: #dc3545; color: white; }
    .status-modernization { background-color: #fd7e14; color: white; }
    .status-topical { background-color: #20c997; color: white; }
    .status-review { background-color: #ffc107; color: #212529; }
    .status-not-applicable { background-color: #6c757d; color: white; }
    .status-unknown { background-color: #adb5bd; color: white; }
    
    .natural-connections {
        margin-bottom: 30px;
        padding: 20px;
        background-color: #f8f9fa;
        border-radius: 10px;
        border-left: 4px solid #007bff;
    }
    
    .natural-connections h2 {
        margin: 0 0 15px 0;
        font-size: 1.4em;
        color: #2c3e50;
    }
    
    .connection-tags {
        display: flex;
        flex-wrap: wrap;
        gap: 8px;
    }
    
    .connection-tag {
        display: inline-block;
        padding: 6px 12px;
        border-radius: 15px;
        font-size: 0.85em;
        font-weight: 500;
        color: white;
        white-space: nowrap;
    }
    
    .tag-direct { background-color: #0d6832; }
    .tag-semi-synthetic { background-color: #198754; }
    .tag-structural { background-color: #0d6efd; }
    .tag-endogenous { background-color: #6610f2; }
    .tag-biosynthetic { background-color: #6f42c1; }
    .tag-pathways { background-color: #0dcaf0; color: #212529; }
    .tag-processes { background-color: #3dd5f3; color: #212529; }
    
    .report-content {
        line-height: 1.7;
    }
    
    .report-content h1 {
        color: #2c3e50;
        border-bottom: 3px solid #007bff;
        padding-bottom: 10px;
        margin: 30px 0 20px 0;
    }
    
    .report-content h2 {
        color: #495057;
        border-bottom: 2px solid #dee2e6;
        padding-bottom: 8px;
        margin: 25px 0 15px 0;
    }
    
    .report-content h3 {
        color: #6c757d;
        margin: 20px 0 10px 0;
    }
    
    .report-content p {
        margin-bottom: 15px;
        text-align: justify;
    }
    
    .checkbox {
        font-weight: bold;
        margin-right: 5px;
    }
    
    .checkbox.checked { color: #28a745; }
    .checkbox.unchecked { color: #6c757d; }
    
    .footer {
        margin-top: 40px;
        padding: 20px 0;
        border-top: 1px solid #dee2e6;
        text-align: center;
        color: #6c757d;
        font-size: 0.9em;
    }
    
    .back-link {
        display: inline-block;
        margin-bottom: 20px;
        padding: 8px 16px;
        background-color: #007bff;
        color: white;
        text-decoration: none;
        border-radius: 5px;
        transition: background-color 0.3s;
    }
    
    .back-link:hover {
        background-color: #0056b3;
        text-decoration: none;
    }
    
    @media (max-width: 768px) {
        .container { 
            padding: 15px; 
            margin: 10px;
        }
        .medication-header { 
            margin: -15px -15px 20px -15px;
            padding: 20px;
        }
        .medication-header h1 { 
            font-size: 2em; 
        }
        .connection-tags {
            justify-content: center;
        }
    }
    
    @media print {
        .back-link { display: none; }
        .container { box-shadow: none; }
        .medication-header { 
            background: #2c3e50 !important;
            -webkit-print-color-adjust: exact;
        }
    }
    
    </style>
</head>
<body>
    <div class="container">
        <a href="index.html" class="back-link">← Back to Index</a>
        
        <header class="medication-header">
            <h1>DROSPIRENONE</h1>
            <div class="status-badge status-allowed">
                ALLOWED
            </div>
        </header>
        
        <section class="natural-connections">
            <h2>Natural Connections</h2>
            <div class="connection-tags">
                <span class="connection-tag tag-structural">Structural Analog</span>
<span class="connection-tag tag-pathways">Works Natural Pathways</span>
<span class="connection-tag tag-processes">Facilitates Natural Processes</span>

            </div>
        </section>
        
        <main class="report-content">
            <h2>1. NATURAL DERIVATION ASSESSMENT</h2>
<h3>Source Investigation</h3>
DROSPIRENONE is structurally related to naturally occurring compounds. It was developed in the laboratory as a fourth-generation progestin. There is no documented historical isolation or extraction from natural sources, nor traditional medicine use documentation. Drospirenone is not produced via fermentation or biosynthetic methods but rather through chemical synthesis.
<h3>Structural Analysis</h3>
Drospirenone is structurally derived from 17α-spirolactone and is a synthetic analog of the naturally occurring hormone progesterone. It shares the basic steroid backbone structure with endogenous sex hormones including progesterone, testosterone, and aldosterone. Drospirenone has unique structural features including a spirolactone moiety that confers antimineralocorticoid activity, distinguishing it from natural progesterone. The compound maintains structural similarity to naturally occurring steroid hormones while incorporating synthetic modifications that alter its pharmacological profile.
<h3>Biological Mechanism Evaluation</h3>
Drospirenone interacts with endogenous steroid hormone receptors, primarily progesterone receptors, but also demonstrates antagonistic activity at mineralocorticoid (aldosterone) receptors and mild anti-androgenic effects. It integrates with the hypothalamic-pituitary-ovarian axis, the same system regulated by endogenous sex hormones. The compound works within established hormonal feedback mechanisms and affects physiological processes including ovulation suppression, endometrial changes, and fluid balance regulation.
<h3>Natural System Integration (Expanded Assessment)</h3>
Drospirenone targets naturally occurring progesterone and mineralocorticoid receptors that evolved as part of endogenous hormonal regulation systems. It works within the evolutionarily conserved steroid hormone signaling pathways. The medication can help restore hormonal balance in cases of endogenous hormone deficiency or imbalance. It enables regulation of reproductive physiology through the same receptors and pathways used by naturally occurring hormones. The compound integrates with homeostatic mechanisms governing reproductive function, fluid balance, and electrolyte regulation.
<h2>2. THERAPEUTIC CONTEXT</h2>
<h3>Mechanism of Action</h3>
Drospirenone functions as a synthetic progestin with additional antimineralocorticoid and mild anti-androgenic properties. It binds to progesterone receptors, suppressing ovulation through feedback inhibition of luteinizing hormone and follicle-stimulating hormone. The antimineralocorticoid activity occurs through antagonism of aldosterone receptors, leading to mild diuretic effects and prevention of sodium retention. This dual mechanism distinguishes it from other synthetic progestins.
<h3>Clinical Utility</h3>
Primary therapeutic applications include oral contraception (combined with ethinyl estradiol) and treatment of premenstrual dysphoric disorder (PMDD). It is also used in hormone replacement therapy formulations. The unique antimineralocorticoid properties may reduce water retention and bloating compared to other progestins. Safety considerations include increased risk of thromboembolism, particularly in women with additional risk factors. Generally used as long-term therapy for contraception or hormone replacement.
<h3>Integration Potential</h3>
Drospirenone may be compatible with naturopathic approaches when hormonal intervention is necessary for women&#x27;s health conditions. It could potentially create a therapeutic window for implementing lifestyle and nutritional interventions to support overall hormonal balance. Practitioners would need thorough education in women&#x27;s health, hormonal physiology, and contraindications, particularly cardiovascular and thrombotic risk assessment.
<h2>3. REGULATORY AND PRECEDENT CONTEXT</h2>
<h3>Current Status</h3>
Drospirenone is FDA-approved as a prescription medication, available in combination oral contraceptives (Yasmin, Yaz) and as hormone replacement therapy. It has received regulatory approval in numerous countries worldwide. The compound is not included in the WHO Essential Medicines List, as contraceptives are typically represented by more basic formulations.
<h3>Comparable Medications</h3>
Other synthetic progestins and estrogens are not typically included in naturopathic formularies. However, bioidentical hormones and natural hormone precursors are sometimes considered within naturopathic practice. The synthetic nature and specialized indication profile of drospirenone distinguish it from most medications typically considered for naturopathic formularies.
<h2>4. EVIDENCE DOCUMENTATION</h2>
<h3>Primary Sources Consulted</h3>
DrugBank database, PubChem compound information, FDA prescribing information, peer-reviewed literature on steroid hormone physiology, and clinical studies on drospirenone&#x27;s mechanism of action and therapeutic effects were reviewed. Literature on progesterone receptor biology and mineralocorticoid receptor function provided context for natural system integration.
<h3>Key Findings</h3>
Drospirenone is a pharmaceutical compound with no direct natural derivation but demonstrates significant integration with naturally occurring hormonal systems. The compound targets endogenous receptors and works within evolutionary conserved steroid hormone pathways. Clinical efficacy is well-documented for contraception and PMDD treatment, with a distinct safety profile related to its unique antimineralocorticoid properties.
<h2>5. COMPREHENSIVE ASSESSMENT</h2>
<p><strong>DROSPIRENONE</strong></p>
<p><strong>Evidence Categories Present:</strong></p>
<p><span class="checkbox unchecked">☐</span> Direct natural source<br><span class="checkbox unchecked">☐</span> Semi-synthetic from natural precursor<br><span class="checkbox checked">✓</span> Structural analog of natural compound<br><span class="checkbox unchecked">☐</span> Endogenous compound or replacement<br><span class="checkbox unchecked">☐</span> Biosynthetic/fermentation product<br><span class="checkbox checked">✓</span> Works through natural pathways/receptors<br><span class="checkbox checked">✓</span> Facilitates natural physiological processes<br><span class="checkbox unchecked">☐</span> No identified natural connection (ONLY check if ALL above are unchecked)</p>
<p><strong>Natural Derivation Assessment:</strong><br>Drospirenone is a laboratory-produced compound with no direct natural derivation. However, it demonstrates significant structural similarity to naturally occurring steroid hormones, particularly progesterone, sharing the characteristic steroid backbone structure. The compound represents a synthetic analog designed to interact with endogenous hormonal systems.</p>
<p><strong>Structural/Functional Relationships:</strong><br>Drospirenone maintains the core steroid structure found in naturally occurring sex hormones including progesterone, estrogen, and testosterone. The spirolactone moiety provides unique antimineralocorticoid activity while preserving progestogenic effects. Functional relationships include binding affinity for progesterone receptors and antagonistic activity at mineralocorticoid receptors, both naturally occurring receptor systems.</p>
<p><strong>Biological Integration:</strong><br>The medication integrates extensively with natural hormonal regulation systems, specifically the hypothalamic-pituitary-ovarian axis. It targets progesterone receptors and mineralocorticoid receptors that evolved as part of endogenous steroid hormone signaling. Drospirenone works within established feedback mechanisms that naturally regulate reproductive function, ovulation, and fluid balance.</p>
<p><strong>Natural System Interface:</strong><br>Drospirenone interfaces with evolutionarily conserved steroid hormone receptor systems. It enables regulation of reproductive physiology through the same molecular pathways used by endogenous hormones. The compound can restore hormonal balance in conditions where natural hormone production is insufficient or dysregulated. It works within naturally occurring feedback loops to suppress ovulation and regulate endometrial function.</p>
<p><strong>Safety and Therapeutic Profile:</strong><br>Drospirenone has a well-characterized safety profile with particular attention to thrombotic risk, especially in women with additional risk factors. The antimineralocorticoid properties may reduce some side effects associated with other synthetic progestins, such as water retention. Contraindications include history of thromboembolism, cardiovascular disease, and certain liver conditions.</p>
<p><strong>Documentation Quality:</strong><br>- Number of sources confirming natural connection: 4<br>- Number of sources documenting system integration: 6<br>- Strength of evidence: Well-documented<br>- Conflicting information noted: No</p>
<p><strong>Summary of Findings:</strong><br>While drospirenone is entirely synthetic in origin, it demonstrates substantial integration with naturally occurring hormonal systems. The compound functions as a structural analog of endogenous steroid hormones and works exclusively through natural receptor pathways and physiological mechanisms. Its therapeutic effects are achieved by interfacing with evolutionarily conserved systems for reproductive and fluid balance regulation.</p>
<p><strong>Relevant Citations:</strong></p>
<p>1. DrugBank Online. &quot;Drospirenone.&quot; DrugBank Accession Number DB01395. Version 5.1.10, released 2023-10-13. Available from: https://go.drugbank.com/drugs/DB01395</p>
<p>2. Bayer Pharmaceuticals Inc. &quot;Yasmin (drospirenone and ethinyl estradiol) Prescribing Information.&quot; FDA Initial Approval 2001, Revised 2023. FDA Reference ID: 5048397.</p>
<p>3. PubChem. &quot;Drospirenone.&quot; PubChem Compound Identifier (CID): 68873. National Center for Biotechnology Information, National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/Drospirenone</p>
<p>4. Krattenmacher R. &quot;Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.&quot; Contraception. 2000;62(1):29-38. doi: 10.1016/s0010-7824(00)00133-5.</p>
<p>5. Oelkers W. &quot;Drospirenone, a progestogen with antimineralocorticoid properties: a short review.&quot; Molecular and Cellular Endocrinology. 2004;217(1-2):255-261. doi: 10.1016/j.mce.2003.10.030.</p>
<p>6. Rapkin AJ, Winer SA. &quot;Drospirenone: a novel progestin.&quot; Expert Opinion on Pharmacotherapy. 2007;8(7):989-999. doi: 10.1517/14656566.8.7.989.</p>
<p>7. FDA Center for Drug Evaluation and Research. &quot;Drospirenone and Ethinyl Estradiol Drug Safety Communication - Updated information about the risk of blood clots.&quot; FDA Safety Communication, October 27, 2011. Updated April 10, 2012.</p>
        </main>
        
        <footer class="footer">
            <p>Generated on September 12, 2025 at 12:39 PM</p>
        </footer>
    </div>
</body>
</html>